Radical primary surgery for advanced-stage ovarian cancer;Die radikale primäroperation des fortgeschrittenen ovarialkarzinoms

Gynakologe

Volumn 39, Issue 10, 2006, Pages 762-767

  Fischer, D ^a,b   Cordes, T ^a   Schroer, A ^a   Diedrich, K ^a   Friedrich, M ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Interval surgery; Intraoperative evaluation; Lymphadenectomy; Neoadjuvant chemotherapy; Ovarian cancer; Resection

Indexed keywords

PLATINUM; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; HUMAN; LYMPHADENECTOMY; OVARY CANCER; PRACTICE GUIDELINE; PROGNOSIS; SURGICAL TECHNIQUE;

EID: 33750720648     PISSN: 00175994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00129-006-1887-1     Document Type: Article

References (29)

1. Aletti GD, Dowdy SC, Gostout BS et al. (2006) Aggressive surgical effort and improved survival an advanced-stage ovarian cancer. Obstet Gynecol 107: 77-85
2. Aletti GD, Dowdy SC, Podratz KC et al. (2006) Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 100: 283-287
3. Aletti GD, Gostout BS, Podratz KC et al. (2006) Ovarian cancer surgical respectability: Relative impact of disease, patient status, and surgeon. Gynecol Oncol 100: 33-37
4. Bristow RE, Montz FJ, Lagasse LD et al. (1999) Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72 (3): 278-287
5. Bristow RE, Montz FJ (2001) Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 83: 39-48
6. Bristow RE, Tomacruz R, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era : A meta-analysis. Clin Oncol 20: 1248-1259
7. Brun JL, Feyler A, Chene G et al. (2000) Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 78 (1): 21-27
8. Crawford SC, Vasey PA, Paul J et al. (2005) Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 23: 8802-8811
9. Denzer U, Hoffmann S, Helmreich-Becker I et al. (2004) Minilaparoscopy in the diagnosis of peritoneal tumor spread: Prospective controlled comparison with computed tomography. Surg Endosc 18: 1067-1070
10. Du Bois A, Rochon J, Lamparter C, Pfisterer J (2005) The quality assurance program of the AGO Organkommission OVAR (QS-OVAR): Pattern of care and reality in Germany. Zentralbl Gynäkol 127 (1): 9-17.http://www.ago-ovar.de
11. Du Bois A, Rochon J, Lamparter C et al. (2005) Impact of center characteristics on outcome in ovarian cancer in Germany. Zentralbl Gynäkol 127: 18-30
12. Eisenkop SM (2002) Thoracoscopy for the management of advanced epithelial ovarian cancer - a preliminary report. Gynecol Oncol 84: 315-320
13. Eisenkop SM, Friedman RL, Wang HJ (1998) Cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian cancer. Gynecol Oncol 69: 103-108
14. Eisenkop SM, Spirtos NM, Lin WC (2006) Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol Oncol 100: 344-348
15. Eitan R, Levine DA, Abu-Rustum N et al.(2005) The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer 103: 1397-1401
16. Kermauner F (1932) Die Erkrankungen des Eierstockes. In: "Handbuch der Gynäkologie". von Bergmann JF, S 525
17. Kuhn W, Schmalfeldt B, Pache L et al. (1998) Disease-adapted relapse therapy for ovarian cancer: Results of a prospactive study. Int J Oncol 13 (1): 57-63
18. Magtibay PM, Adams PB, Silverman MB et al. (2006) Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol 21, epub
19. Marx CI, Moller C Bendixen A et al. (2006) Ovarian cancer in Denmark. Status of the surgical intervention. Ugeskr Laeger 168: 1537-1540
20. Panici PB, Maggioni A, Hacker N et al. (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomized clinical trial. J Natl Cancer Inst 97 (8): 560-566
21. Piver MS, Barlow JJ (1976) Preoperative and intraoperative evaluation in ovarian malignancy. Obstet Gynecol 48: 312-315
22. Roh JW, Seo SS, Lee S et al. (2005) Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: A prospective surgicopathologic correlation study. Eur J Cancer 41: 2086-2092
23. Scarabelli C, Gallo A, Franceschi S et al. (2000) Primary cytoreductive surgery with rectosimoid colon resection for patients with advanced epithelial ovarian cancer. Cancer 88: 389-397
24. Schmid H (1953) Klinik der Eierstockgeschwülste. In: Seitz (Hrsg) Biologie und Pathologie des Weibes. Urban & Schwarzenberg, München, S 758
25. Tagjitgamol S, Manusirivithaya S, Sheanakul C et al. (2003) Can we rely on the size of the lymph node in determining nodal metastasis in ovarian carcinoma? Int J Gynecol Cancer 13 (3): 297-302
26. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003) Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101: 885-891
27. Van der Burg ME, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithalial ovarian cancer. Gynecological cancer cooperative group of the European organization for research and treatment of cancer. N Engl J Med 332: 629-634
28. Wright JD, Herzog TJ, Powell MA (2004) Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol 190: 1398-1400
29. Young RC, Decker DG, Wharton JT et al. (1983) Staging laparotomy in early ovarian cancer. JAMA 250 (22): 3072-3076